A1LN34:BVMF
Alnylam Pharmaceuticals Inc Bdr
R$ 59.84
0.00%
(0.00) Siku 1
16 Okt, 16:56:00 GMT -3 · BRL
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya A1LN34...
Fungua
R$ 59.28
Juu
R$ 59.84
Chini
R$ 59.28
Mtaji wa soko
31.02B
Wastani wa kiasi cha mauzo
446.00
Kiasi cha mauzo ya hisa
17.00
Juu kwa wiki 52
R$ 131.80
Chini kwa wiki 52
R$ 50.25
Hisa za wawekezaji
133.81M
Idadi ya wafanyakazi
elfu 2
Fungua
R$ 59.28
Juu
R$ 59.84
Chini
R$ 59.28
Mtaji wa soko
31.02B
Wastani wa kiasi cha mauzo
446.00
Kiasi cha mauzo ya hisa
17.00
Juu kwa wiki 52
R$ 131.80
Chini kwa wiki 52
R$ 50.25
Hisa za wawekezaji
133.81M
Idadi ya wafanyakazi
elfu 2
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
ad-hoc-news.de
·
saa 7 zilizopita
BofA cuts target to USD 336.00 for Alnylam Pharmaceuticals stock
ad-hoc-news.de
·
siku 2 zilizopita
Citigroup cuts target to USD 320 for Alnylam Pharmaceuticals stock
Wasifu
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
Kuhusu Alnylam Pharmaceuticals Inc Bdr
Afisa Mkuu Mtendaji (CEO)-
Wafanyakazielfu 2.5
Lilianzishwa14 Jun 2002
Makao makuu-
Sekta-
Tovutialnylam.com